| Overview |
| bs-5231R-APC-Cy5 |
| Bid (Ser61) Polyclonal Antibody, APC-Cy5 Conjugated |
| WB, FCM, IF(IHC-P), IF(IHC-F), IF(ICC) |
| Human |
| Mouse |
| Specifications |
| APC-Cy5 |
| Rabbit |
| KLH conjugated synthetic phosphopeptide derived from mouse Bid around the phosphorylation site of Ser61 |
| Ser61 |
| Polyclonal |
| IgG |
| 1ug/ul |
| Purified by Protein A. |
| Aqueous buffered solution containing 0.01M TBS (pH7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol. |
| Store at -20°C. Aliquot into multiple vials to avoid repeated freeze-thaw cycles. |
| Target |
| 12122 |
| Cytoplasm, Cell membrane |
| Bid phospho S61; p-Bid phospho S61; BH3 interacting domain death agonist; p22 BID; BID; BH3-interacting domain death agonist; AltName: BH3-interacting domain death agonist p15; BH3-interacting domain death agonist p13; p13 BID; BH3-interacting domain death agonist p11; p11 BID. |
| Bid, a BH3 domain containing proapoptotic Bcl2 family member, is localized in the cytosolic fraction of cells as an inactive precursor. Its active form is generated upon proteolytic cleavage by caspase 8 in the Fas signaling pathway. Cleaved Bid translocates to mitochondria and releases its potent proapoptotic activity, which in turn induces cytochrome c release and mitochondrial damage. The cytochrome c releasing activity of Bid was antagonized by Bcl2. Mutation in the SH3 domain can diminish the cytochrome c releasing activity. In animal model studies, Bid deficient mice are found resistant to the lethal effects of death factor signals relayed through Fas. |
| Application Dilution |
| WB |
1:300-5000 |
| FCM |
1:20-100 |
| IF(IHC-P) |
1:50-200 |
| IF(IHC-F) |
1:50-200 |
| IF(ICC) |
1:50-200 |
Powered by Bioz